WIA
ACET icon

Wealthedge Investment Advisors’s Adicet Bio ACET Stock Holding History

Wealthedge Investment Advisors’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,753
Closed -$243K – 133
2025
Q3 		$243K Sell
18,753
-816
-4% -$9.62K 0.09% 115
2025
Q2 		$191K Buy
19,569
+5,331
+37% +$56.2K 0.08% 135
2025
Q1 		$172K Buy
14,238
+9,628
+209% +$138K 0.08% 163
2024
Q4 		$71K Buy
+4,610
New +$87K 0.03% 165

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Wealthedge Investment Advisors's ACET Position: Q4 2025 in Review

Wealthedge Investment Advisors sold out of Adicet Bio (ACET) in Q4 2025, closing a stake of 18,753 shares — an estimated $243K sold.

Wealthedge Investment Advisors first reported a position in ACET in Q4 2024 and held it in 4 quarters. The position peaked at $243K in Q3 2025. 49 funds tracked by Wall St. Rank hold ACET as of Q4 2025.

  • Wealthedge Investment Advisors reported no remaining Adicet Bio position as of Q4 2025 after selling out during the quarter.
  • Wealthedge Investment Advisors sold 18,753 Adicet Bio shares in Q4 2025, an estimated $243K.
  • Wealthedge Investment Advisors first reported a position in Adicet Bio in Q4 2024 and held it in 4 quarters.
  • Wealthedge Investment Advisors's Adicet Bio position peaked at $243K in Q3 2025.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2025.

Based on Wealthedge Investment Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.